Athyrium Capital Management, LP
Follow13F filer, CIK 1728001, New York, NY
Athyrium Capital Management, LP reported $33,539,393 across 3 holdings for the quarter ended 2024-06-30, in a 13F-HR filed 2024-08-08.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-24-000213
- Period
- 2024-06-30
- Reported value
- $33.5M
- Holdings
- 3
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 1
Holdings, Q2 2024
Share positions as resolved from 13F-HR 0001123292-24-000213, largest first. % of portfolio is the value over $33,539,393, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| BIORA THERAPEUTICS INCBIORA THERAPEUTICS INC | 10,929,762 | $7.21M | 21.51% | 0 | |||
| PBYIPUMA BIOTECHNOLOGY INC | 1,256,411 | $4.1M | 12.21% | 0 | Timeline |
Principal amounts
Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).
| Security | Type | Amount | Value | Change |
|---|---|---|---|---|
| COHERUS ONCOLOGY INCCOHERUS ONCOLOGY INC BOND | principal | 30,000,000 | $22.2M | new |
Sold out in Q2 2024
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| OMEROS CORPOMEROS CORP | 72,979,000 | $54.1M | principal |
How Q2 2024 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001123292-24-000213 | base | 2024-08-08 | acceptance time not in the bulk data set |